In plain words

Two placebo-controlled trials, one of 150 adults taking 120 mg a day for six weeks and one of 80 people over eight weeks (the ledger has no dose for the second), both found better sleep in the groups taking ashwagandha. In the smaller trial the gain was larger in people with insomnia.

The short answer

Both randomized trials in the ledger found better sleep with ashwagandha than with placebo. Deshpande and colleagues (2020) gave 150 healthy adults with non-restorative sleep 120 mg a day for six weeks; self-reported sleep quality rose 72%, against 29% on placebo. Langade and colleagues (2020) found improved sleep measures in 80 healthy and insomnia participants over eight weeks, more so with insomnia; the ledger has no dose for this trial. Two meta-analyses (2021, 2025) report pooled gains that may include these trials, so they add no separate evidence. Certainty is low, because the two trials are short and small, and the ledger has no funding for either.

The 60-second version

Every study in the video is listed below, with its quote.

Watch on YouTube

Where the evidence sits

Sleep improved

■ Randomized trial, Deshpande et al., 2020 · 150 people · six weeks
■ Randomized trial, Langade et al., 2020 · 80 people · 8-weeks · another measure depended on conditions
◪ Pooled analysis, Cheah et al., 2021 · may overlap studies counted here · Pittsburgh index no significant difference
◪ Pooled analysis, BJPsych Open systematic review and meta-analysis, 2025 · may overlap studies counted here
□ Review, NCCIH (NIH), 2023 · summarises other studies

■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data

Evidence weight5555 / 100?

Who says what

SourceFindingDesignPeopleDose and lengthFunding and independence
Deshpande et al., 2020Sleep quality up 72% vs 29% on placeboRandomized, placebo-controlled150 adults, non-restorative sleep120 mg daily, 6 weeksNot in ledger
Langade et al., 2020Sleep improved, more with insomniaRandomized, placebo-controlled80, healthy and insomniaDose not in ledger; 8 weeksNot in ledger
Cheah et al., 2021Small overall gain; no significant Pittsburgh index differenceMeta-analysis that may include the trials above400120 to 600 mg daily, 6 to 12 weeksNot in ledger
BJPsych Open meta-analysis, 2025Pooled sleep quality gainMeta-analysis that may include the trials aboveNot in ledgerNot in ledgerNot in ledger
NCCIH (NIH), 2023Some preparations may help insomniaGovernment agency summarizing researchNoneNot in ledgerNIH agency
Deshpande et al., 2020

Sleep quality up 72% vs 29% on placebo

Design
Randomized, placebo-controlled
People
150 adults, non-restorative sleep
Dose and length
120 mg daily, 6 weeks
Funding
Not in ledger
Langade et al., 2020

Sleep improved, more with insomnia

Design
Randomized, placebo-controlled
People
80, healthy and insomnia
Dose and length
Dose not in ledger; 8 weeks
Funding
Not in ledger
Cheah et al., 2021

Small overall gain; no significant Pittsburgh index difference

Design
Meta-analysis that may include the trials above
People
400
Dose and length
120 to 600 mg daily, 6 to 12 weeks
Funding
Not in ledger
BJPsych Open meta-analysis, 2025

Pooled sleep quality gain

Design
Meta-analysis that may include the trials above
People
Not in ledger
Dose and length
Not in ledger
Funding
Not in ledger
NCCIH (NIH), 2023

Some preparations may help insomnia

Design
Government agency summarizing research
People
None
Dose and length
Not in ledger
Funding
NIH agency

What did the two trials find?

Deshpande and colleagues (2020) gave 150 healthy adults with non-restorative sleep 120 mg of extract or placebo daily for six weeks; 144 finished, with no dropouts due to adverse events. They report self-reported sleep quality:

A 72% increase in self-reported sleep quality was found for the treatment group, compared with 29% in the placebo group (p < 0.001).

Activity monitors in the same trial showed improved sleep efficiency, total sleep time, time to fall asleep and time awake at night against placebo.

Langade and colleagues (2020) tested root extract against placebo for eight weeks in 80 healthy and insomnia participants; the ledger has no dose for this trial. Time to fall asleep and sleep efficiency improved most, and the authors compared the two groups:

The improvement was found more significant in insomnia subjects than healthy subjects.

What do the pooled analyses add?

Cheah and colleagues (2021) pooled five randomized studies with 400 participants at 120 to 600 mg a day for 6 to 12 weeks, a pooled estimate that may include the trials above. It found a small gain in overall sleep but no significant difference on the Pittsburgh Sleep Quality Index in a subset of 131 participants, for which the ledger has no dose or duration. The review also looked at subgroups:

The effects on sleep were more prominent in the subgroup of adults diagnosed with insomnia, treatment dosage ≥600 mg/day, and treatment duration ≥8 weeks.

It reported no serious adverse effects in any pooled study. A 2025 BJPsych Open meta-analysis also pooled a sleep quality gain that may include the trials above; the ledger has no n, dose or duration for it. NCCIH (2023), an NIH agency summarizing research, writes that some preparations "may be effective for insomnia".

Why the sources disagree

No two measurements in the ledger contradict each other on sleep. The split is between measures: inside Cheah and colleagues' (2021) review, a pooled estimate that may include the trials above found a small overall gain but no significant Pittsburgh index difference. The trials also differ in people and dose: 150 adults with non-restorative sleep at 120 mg a day for six weeks, against 80 healthy and insomnia participants for eight weeks with no dose in the ledger. The ledger has no funding for any study.

What would settle it

An independently funded, pre-registered trial randomizing adults with diagnosed insomnia and healthy poor sleepers to 120 mg, 600 mg or placebo daily for 12 weeks, reporting the Pittsburgh Sleep Quality Index and activity-monitor sleep against placebo, with a check four weeks after stopping. A matching result from a second research group would raise certainty from low to moderate.

How this page was made

The 5 sources are two randomized trials and two meta-analyses, each a pooled estimate that may include the trials above, from a PubMed literature check, plus the NCCIH fact sheet; rodent studies and disease populations were left out. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.

Changelog: 25 Sep 2026, first version, 5 sources.